Background: The objective of the study was to investigate the activity of sunitinib in a cell line model and subsequently in patients with cisplatin-refractory or multiply relapsed germ cell tumors (GCT).
introduction
Although the vast majority of patients with metastatic germ cell tumors (GCT) are cured, those with cisplatin-refractory relapse or relapse after high-dose chemotherapy (HD-CT) still exhibit a very poor prognosis, and <5% of these patients will achieve long-term survival [1] . For these patients, the evaluation of new active drugs and treatment combinations remains a priority.
Various agents have been evaluated in intensively pretreated or cisplatin-refractory patients. As single agents, only paclitaxel, gemcitabine, oxaliplatin, and orally administered etoposide have been shown to be active, with selected patients achieving long-term survival [2] [3] [4] [5] [6] . Different combinations of these agents demonstrated response rates up to 51%, including 10%-15% long-term survivors, although duration of remission is usually moderate [7] [8] [9] [10] .
The molecular mechanisms involved in cisplatin resistance are still incompletely understood. Mismatch repair deficiency and microsatellite instability are thought to be associated with cisplatin resistance in human GCT [11] . Preliminary studies suggest that vascular endothelial growth factor (VEGF) may play an important role in development and metastasizing of original article
GCT [12] [13] [14] . A substantially higher VEGF and platelet-derived growth factor (PDGF) expression has been found in patients with GCT compared with normal testis tissue in several studies, indicating that VEGF and PDGF expression could play an important role in tumor angiogenesis, tumor progression, and metastases [12] [13] [14] [15] . A significantly higher progression-free survival (PFS) rate was seen in a murine testicular cancer xenograft model when an angiostatic agent was combined with carboplatin or cisplatin as compared with either carboplatincisplatin or the angiostatic agent alone [16, 17] . Sunitinib is an orally administered small molecule and a potent multityrosine kinase inhibitor for VEGF receptor, PDGF receptor, as well as the stem cell factor receptor c-KIT. Sunitinib has demonstrated clinical activity in several tumors including thymic carcinoma and pancreatic neuroendocrine tumors, and is currently approved for the treatment of gastrointestinal stromal tumors and renal cell carcinoma.
Based on this rationale, we used a cell line model to investigate the preclinical activity of sunitinib in different GCT cell lines with defined levels of cisplatin resistance by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Having observed in vitro activity of sunitinib in cisplatinresistant GCT cell lines at the same level as in their cisplatinsensitive counterparts, we carried out a phase II study in patients with cisplatin-refractory or multiply relapsed GCT.
patients and methods

preclinical study
Sunitinib was kindly provided by Pfizer Inc., Berlin, Germany, and was dissolved in dimethyl sulfoxide (DMSO). Cisplatin was obtained from Teva, Radebeul, Germany, and was dissolved in 0.9% saline. NTERA2 cells, first described by Andrews [18] , were obtained from the 'Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH', Braunschweig, Germany. NCCIT cells, first described by Teshima et al. [19] , were obtained from American Type Culture Collection, Manassas, VA. 2102Ep cells were kindly provided by L. Looijenga, Rotterdam, The Netherlands.
NCCIT and 2102Ep cells were cultured in Dulbecco's modified Eagle's medium (DMEM) and F12 medium (1 : 1) (Gibco-BRL; Invitrogen, Paisley, UK) containing 10% fetal calf serum (FCS) (Gibco-BRL; Invitrogen), and NTERA2 cells with DMEM supplemented with Glutamax-I (Gibco-BRL; Invitrogen) containing 10% FCS (Gibco-BRL; Invitrogen). Cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 .
From these well-established GCT cell lines, all derived from human embryonal carcinomas, cisplatin-resistant sublines exhibiting 5.2-12.2-fold increase in cisplatin resistance were generated in our laboratory over a time period of 18 months by intermittent exposure to increasing doses of cisplatin, starting with the IC 50 (concentration that causes 10% inhibition of growth) dose of the parental cell lines. At reaching 50% lethality, the addition of cisplatin was paused and cells were allowed to recover over three passages until the next dose escalation step.
The MTT assay was carried out as previously described [20] . The MTT assay is based on the cleavage of the tetrazolium salt MTT to purple formazan crystal by metabolically active cells. In brief, the cell lines were rinsed with phosphate-buffered saline, trypsinized, and resuspended in 1 ml of the appropriate culture medium to count the cells in a hemaocytometer chamber. In total, 4 · 10 3 cells per well were seeded in 96-well plates to ensure logarithmic growth. Cells were allowed to adhere over night, and serial dilutions of the chemotherapeutic agents were added to octuplicate wells at concentrations from 0.2 to 25.6 lM of both sunitinib and cisplatin. The cells were exposed to the drug for 48 h. Thereafter, the drug-containing medium was removed and 0.2 ml MTT solution (final concentration: 0.5 mg/ml MTT; Sigma, Hamburg, Germany) was added. The plates were incubated for 2 h before the medium was removed and 0. Adequate bone marrow function (neutrophils >1500/ll, platelet count >100 000/ll), liver function (bilirubin <1.5-fold upper normal limit), and renal function (serum creatinine £twofold upper normal limit) were mandatory. All patients gave written informed consent. The study (clinical trial identifier: NCT00371553) was approved by the ethics committees of the British Columbia Cancer Agency and the University of Hamburg-Eppendorf, Germany, as well as by local ethics committees of all participating centers. Sunitinib was given at a dose of 50 mg daily for 4 weeks followed by a 2-week break to form 6-week cycles. Dose reductions to 37.5 or 25 mg daily for 4 weeks on/2 weeks off were recommended for significant toxicity. No more than two dose reductions were permitted in any patient. If clinically deemed appropriate or necessary by the investigator, a continuous administration schedule utilizing 37.5 or 25 mg daily without breaks was allowed. Intrapatient reescalation back to the previous dose level was permitted in the absence of grade ‡3 hematologic or grade ‡2 non-hematologic toxicity in the previous cycle. Treatment was continued until disease progression, occurrence of unacceptable toxicity, intercurrent illness that prevented further administration of therapy, or patient's decision to withdraw from the study.
Pretreatment evaluation consisted of medical history, assessment of the Karnofsky performance status, physical examination, electrocardiogram, Multi Gated Acquisition Scan or echocardiogram, routine laboratory, thyroid function tests, urinnalysis, tumor markers (AFP and b-HCG), as well as radiological tumor assessments.
definitions Disease was considered cisplatin refractory when at least tumor stabilization or a remission had been achieved during cisplatin-based chemotherapy, but tumor progression occurred again within 4 weeks of the last cisplatin-based chemotherapy. Disease was considered absolutely cisplatin refractory when tumor progression had occurred while patients were receiving cisplatinbased therapy [21, 22] .
response/toxicity assessment
Response assessments were carried out on day 28 of each 6-week cycle. Response was evaluated according to RECIST version 1.0 criteria [23] . In addition, patients with reduction of the size of a tumor lesion and normalization of previously elevated tumor markers were considered partial remission with tumor marker normalization (PR negative 
statistical considerations
The primary end point of this study was response rate. Tolerability, PFS, and overall survival (OS) time represented secondary end points. An optimal Simon two-stage design was used to determine the number of patients required [24] . Assuming a response rate of clinical interest of >20%, a minimal response rate of 5%, a probability of 5% for rejecting an active drug combination (type II error), and a probability of 20% to further evaluate an ineffective drug combination (type I error), 16 patients had to be enrolled into the first cohort. If no response to study therapy was observed among the first 16 patients, the study was to be terminated. If at least one objective remission occurred, the study was to be continued with a second cohort of 16 patients. (Figure 1 ). Apart from NTERA2-R, which were slightly more sensitive to sunitinib than NTERA2 (P = 0.02), there was no difference in sensitivity to sunitinib between cisplatin-sensitive parental cell lines and their cisplatin-resistant sublines, demonstrating that there is no cross-resistance of cisplatin and sunitinib in GCT cell lines in vitro.
clinical study
Thirty-three patients with heavily pretreated or cisplatinrefractory GCT were entered into the study between February 2007 and January 2010. Patient characteristics are listed in Table 1 .
Fifteen percent of patients had a primary mediastinal GCT. All patients were heavily pretreated with a median number of 2 (range, 1-6) platinum-based regimens. Sixty-six percent of patients had relapsed after HD-CT, and 33% were considered late relapses ( ‡2 years after initial therapy). Fifty-four percent of patients were considered cisplatin refractory or absolutely refractory.
A total of 66 cycles of sunitinib were administered with a median number of 1 cycle per patient (range, 1-9). No complete remission was observed. Three patients achieved a partial remission (9%) ( Tables 2 and 3 ). Time to progression for these three patients was 5.0, 6.4, and 12.2 months. One additional seminoma patient achieved a response but subsequently went off study before a confirmatory scan was carried out (Table 3) . Stable disease was recorded for 41% of patients with a median duration of 2.3 months (range 1.6-6.5 months).
After a median follow-up of 14.4 months (range, 6-18 months), all patients are off study. In 30 patients, treatment termination was due to progression, 2 patients refused further treatment, and 1 patient was stopped due to hyperbilirubinemia. Median PFS for all patients was 2.0 months [95% confidence interval (CI) 1.4-2.60], with 11% and 3.7% of patients being progression free at 6 and 12 months, respectively (Figure 2 ). Median OS was 3.8 months (95% CI 3.0-6.6), with 36.4% and 9.9% of patients being alive at 6 and 12 months, respectively.
Sunitinib treatment was feasible and toxicity in these heavily pretreated patients was generally acceptable. However, treatment duration was short in the majority of patients and thus toxicity assessment, and in particular evaluation of longterm toxicity, is limited ( Table 4 ). The most common sunitinib-related toxic effects included fatigue (39%), anorexia (21%), diarrhea (27%), mucositis (45%), nausea/vomiting (24%), and dyspepsia (27%). Grade 3/4 toxic effects were rare and no unexpected side-effects were observed.
discussion
Despite the overall success of cisplatin-based chemotherapy in patients with metastatic GCT, the prognosis for cisplatin- Figure 1 . IC 50 (concentration that causes 50% inhibition of growth) values of cisplatin and sunitinib in three embryonal carcinoma cell lines (NTERA2, 2102Ep, and NCCIT) and their derivatives, relatively cisplatinresistant sublines NTERA2-R, 2102Ep-R, and NCCIT-R. Cells were treated with either cisplatin or sunitinib for 48 h. Whereas the differences between the IC 50 values for cisplatin-sensitive parental and their cisplatin-resistant sublines were all statistically significant ( à P < 0.001), differences in sensitivity to sunitinib were only significant for NTERA2-R versus NTERA, with the cisplatin-resistant line showing better sensitivity than the cisplatin-sensitive cell line ( P = 0.02).
original article Annals of Oncology refractory patients remains very poor. Gemcitabine-oxaliplatin and paclitaxel-gemcitabine or gemcitabine-oxaliplatinpaclitaxel are the most commonly used regimens for these patients resulting in response rates of 25%-40%, with selected patients achieving prolonged survival [7] [8] [9] 25] . Limited clinical data exist regarding targeted therapies in GCT [26, 27] . Based on previous reports on the potential role of VEGF and VEGFR and the very high expression of tyrosine kinases in GCT, we investigated the multityrosine kinase inhibitor sunitinib preclinically and subsequently clinically in cisplatin-resistant GCT [28] . Analysis of the efficacy of sunitinib in GCT cell lines in vitro demonstrated inhibition of proliferation (MTT assay) at an IC 50 in the range of 3.0-3.8 lM after 48 h of drug exposure. There was no difference between cisplatin-sensitive and cisplatin-resistant cell lines, indicating that there is no cross-resistance between sunitinib and cisplatin. Furthermore, this dose range for in vitro activity is at the lower end of previously determined doses in different other tumor cell lines including renal cell carcinoma, nasopharyngeal carcinoma, or lung cancer, where IC 50 doses of 3-10 lM have been reported [29] [30] [31] . An IC 50 of 6 lM has previously been reported for the human yolk sac tumor cell line 1411H after 24-h treatment [17] . As was the case in our three cell lines and their cisplatinresistant sublines, no cross-resistance between cisplatin and sunitinib was observed by Castillo-Avila et al. [17] who, in addition to direct action on receptor tyrosine kinases, also did observe a strong antiangiogenic effect of sunitinib in GCT xenografts. This suggests that in GCT cells, resistance to cisplatin does not confer resistance to sunitinib. Despite this promising preclinical activity of sunitinib in cisplatin-resistant GCT cells, shown both in vitro in our analysis and in vivo by Castillo-Avila et al. [17] , sunitinib exhibited only modest activity with three confirmed temporary partial responses (PRs) in patients with cisplatin -refractory or multiply relapsed GCT and thus our study failed to meet its primary end point of a 20% response rate.
This study was conducted in a prognostically unfavorable group of patients, comparable with those treated within our previous trials evaluating the role of paclitaxel, gemcitabine, and oxaliplatin, or the combination of gemcitabine-paclitaxel in relapsed GCT [7] [8] [9] . Thirty-three percent of the patients presented with a late relapse, 15% initially had presented with a primary mediastinal GCT, 66% were pretreated with HD-CT, and 54% of our patients were classified as cisplatin refractory (Table 1 ). In addition, the majority of patients had also been pretreated with gemcitabine, paclitaxel, and/or oxaliplatin or combinations of these drugs. The PR rate of 13% and disease stabilization rate of 41% with 11% of patients being progression free at 6 months suggest activity in this patient population but is lower than the response rates of 25%-45% recently reported for conventional combination chemotherapy such as oxaliplatin-gemcitabine ( Table 2) . Achieving a high response rate in refractory patients, as seen in studies with combination regimens, e.g. gemcitabineoxaliplatin, is important because the induction of a response may subsequently allow the resection of residual masses and may thus be a chance to still achieve long-term survival. This is underlined by a proportion of 10%-15% of long-term survivors in the trials with conventional chemotherapy [10] . No complete remission was observed in the current trial with sunitinib. Interestingly, however, three of the responding patients were classified as cisplatin refractory before sunitinib therapy. Two patients had refractory seminoma, which can harbor c-KIT mutations as a potential target for sunitinib [32, 33] . Further molecular analysis of these cases is warranted to potentially identify predictive factors for response to sunitinib. Forty-one percent of patients in our study achieved disease stabilization, although the duration of stabilization was generally brief and nonresponding patients progressed rapidly, similar to the duration of stable disease seen in previous chemotherapy studies. It remains unclear whether off-target activity of sunitinib may have contributed to the activity seen in our study. However, any activity in refractory GCT patients is uncommon, and the overall control rate seen in this study is noteworthy and suggests that further investigation of antiangiogenic agents, in particular in combination with chemotherapy, is warranted.
Sunitinib was associated with acceptable toxicity in this heavily pretreated patient population. No unexpected toxic effects were observed, and myelotoxicity was not treatment limiting in these extensively pretreated patients. However, the majority of patients received sunitinib only for a short period of time, which limits our assessment of toxicity.
Our results are slightly better than results previously reported in another small exploratory phase II trial [34] . In this trial, some marker decline was seen; however, no objective response was observed, and the trial was stopped prematurely after enrollment of only 10 patients.
In summary, sunitinib appears to have good preclinical activity and antitumor responses were observed in refractory GCT suggesting a role of the VEGF pathway in GCT. Exploring the molecular characteristics of responding patients may allow the identification of a molecular profile suitable for sunitinib or treatment with other targeted therapies. However, taking into account the results by Feldman et al. [34] as well as our results, it is unlikely that sunitinib as a single agent will clinically play a major role in cisplatin-refractory patients at standard doses and standard schedules unless the underlying mechanism of response to sunitinib is identified. GCT as a highly chemotherapy-sensitive malignancy may provide an opportunity to combine sunitinib with classic cytotoxic cisplatin-based chemotherapy [17, 35] . Ramasubbaiah et al. [36] recently published preliminary data on the combination of oxaliplatin and bevacizumab. Five of eight patients with late relapse responded, suggesting some activity of a combination approach in this particular patient population. A major concern, however, with regard to combination treatment using a multityrosine kinase inhibitor like sunitinib and a cytotoxic drug is overlapping and often additive toxicity, e.g. myelosuppression [37, 38] . Further research to unravel the molecular biology of testicular GCT and in particular the mechanisms of chemotherapy resistance is urgently needed, but the identification of new targets will hopefully allow more tailored therapy approaches in GCT. 
